Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 168,544 | 157,132 | 168,022 | 126,713 | 211,574 |
| Marketable Securities | 42,301 | 37,847 | 30,269 | 33,685 | 34,658 |
| Receivables | 600 | N/A | N/A | 150 | 469 |
| Income taxes - deferred | 10,054 | 13,540 | 10,442 | 17,057 | 19,902 |
| TOTAL | $233,513 | $218,196 | $212,431 | $185,392 | $284,663 |
| Non-Current Assets | |||||
| PPE Net | 22 | 36 | 51 | 65 | 80 |
| Investments And Advances | 17,101 | 30,356 | 38,030 | 33,065 | 1,997 |
| Other Non-Current Assets | 18,835 | 21,937 | 33,749 | 30,182 | 29,926 |
| TOTAL | $35,958 | $52,329 | $71,830 | $63,312 | $32,003 |
| Total Assets | $269,471 | $270,525 | $284,261 | $248,704 | $316,666 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 528 | 272 | 124 | 286 | 2,540 |
| Accrued Expenses | 120,870 | 142,768 | 150,746 | 145,177 | 184,247 |
| Other current liabilities | N/A | N/A | 4,270 | N/A | N/A |
| TOTAL | $133,007 | $173,568 | $217,023 | $346,958 | $193,991 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 0 | 18,454 | 66,282 | 85,023 |
| Deferred Revenues | N/A | N/A | 1,713 | 1,713 | N/A |
| Other Non-Current Liabilities | 340,737 | 340,196 | 342,291 | 206,668 | 361,834 |
| TOTAL | $340,737 | $340,196 | $360,745 | $272,950 | $446,857 |
| Total Liabilities | $473,744 | $513,764 | $577,768 | $619,908 | $640,848 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 139,875 | 139,835 | 139,795 | 139,680 | 139,680 |
| Common Shares | 1,397 | 1,397 | 1,397 | 1,396 | 1,396 |
| Retained earnings | -42,035 | -80,977 | -126,893 | -196,879 | -241,424 |
| Other shareholders' equity | -1,885 | -1,770 | -5,996 | -4,590 | 3,219 |
| TOTAL | $-204,273 | $-243,239 | $-293,507 | $-371,204 | $-324,182 |
| Total Liabilities And Equity | $269,471 | $270,525 | $284,261 | $248,704 | $316,666 |